Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) provides specialty pharmaceutical solutions for critical care and underserved medical needs. This news hub offers investors and healthcare professionals verified updates on the company's FDA-approved therapies, clinical developments, and strategic initiatives.
Access timely reports on product approvals, clinical trial milestones, and corporate partnerships across Cumberland's core therapeutic areas: hospital acute care, oncology support, gastroenterology treatments, and rare disease therapies. Our curated news collection enables informed decision-making through coverage of financial results, regulatory submissions, and market expansion efforts.
Key updates include developments for Cumberland's Ifetroban clinical program targeting rare conditions, international distribution agreements, and innovations in pain management solutions like Caldolor®. All content undergoes strict verification to ensure accuracy and relevance for stakeholders.
Bookmark this page for centralized access to CPIX's latest pharmaceutical advancements and corporate announcements. Check regularly for essential updates impacting the specialty medicine sector.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced new research comparing Caldolor (ibuprofen injection) to ketorolac in over 150,000 patients. The study, published in Frontiers of Pain Research, analyzed 31,046 Caldolor and 124,184 ketorolac adult patients, plus 5,579 pediatric patients in each arm. Results showed Caldolor associated with 45% reduction in renal dysfunction and 78% decrease in hematuria rates in adults compared to ketorolac. In pediatric patients, Caldolor showed 51-65% lower adverse drug reaction rates. The medication also demonstrated improved healthcare resource utilization with decreased emergency room visits, outpatient visits, and shorter hospital stays.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its third quarter 2024 financial results after market close on November 7, 2024, followed by a conference call at 4:30 p.m. Eastern Time. The company is a specialty pharmaceutical firm with a portfolio of six FDA-approved brands targeting hospital acute care, gastroenterology, and oncology markets. Their products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Additionally, Cumberland has Phase II clinical programs evaluating ifetroban for various conditions including Systemic Sclerosis, Duchenne Muscular Dystrophy-associated cardiomyopathy, and Idiopathic Pulmonary Fibrosis.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported 16% sequential revenue growth in Q2 2024, with net revenue reaching $9.9 million. The company achieved adjusted earnings of $0.2 million, a $0.8 million improvement over Q1 2024. Key developments include:
1. Kristalose added to Wisconsin Medicaid formulary and recommended in AGA guidelines
2. New study supports Vibativ as an effective treatment for anthrax infections
3. Progress in ifetroban clinical trials for various indications
4. New manufacturing and supplies of Sancuso
5. Potential Medicare reimbursement for Caldolor under the NOPAIN Act
Cumberland's CEO expressed optimism about the company's future, projecting significant revenue growth and positive cash flow from operations in 2024.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, will release its second quarter 2024 financial results after market close on Tuesday, Aug. 6, 2024. A conference call will follow at 4:30 p.m. Eastern Time. The company focuses on providing unique products for hospital acute care, gastroenterology, and oncology markets. Cumberland's portfolio includes FDA-approved brands such as Acetadote®, Caldolor®, Kristalose®, Omeclamox®-Pak, Sancuso®, Vaprisol®, and Vibativ®. Additionally, Cumberland has Phase II clinical programs evaluating ifetroban for cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis, and recently received FDA clearance for a Phase II study in Idiopathic Pulmonary Fibrosis patients.
Cumberland Pharmaceuticals Inc. reported $8.5 million in combined revenues for the first quarter of 2024. The company has $82 million in total assets, $54 million in total liabilities, and $27 million in shareholders' equity. Recent developments include a special report on Caldolor, eligibility for Medicare reimbursement under the NOPAIN Act, new manufacturing of Sancuso, and clinical studies on ifetroban. Financially, net revenue was $8.5 million, with a net loss of $1.9 million and adjusted earnings of a $0.6 million loss. Cumberland continues to focus on innovative products for hospital acute care, gastroenterology, and oncology segments.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) will release its first quarter 2024 financial results on May 7, 2024. The company focuses on specialty pharmaceuticals for hospital acute care, gastroenterology, and oncology. They have FDA-approved products for various conditions and are conducting Phase II clinical trials for new treatments.
FAQ
What is the current stock price of Cumberland Pharmaceuticals (CPIX)?
What is the market cap of Cumberland Pharmaceuticals (CPIX)?
